Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors

Int Arch Allergy Immunol. 2008:146 Suppl 1:7-10. doi: 10.1159/000126053. Epub 2008 May 27.

Abstract

Background: Acetylation and deacetylation of proteins occur in cells in response to various stimuli, and are reversibly catalyzed by histone acetyltransferase and histone deacetylase (HDAC), respectively. EoL-1 cells have an FIP1L1-PDGFRA fusion gene that causes transformation of eosinophilic precursor cells into leukemia cells. The HDAC inhibitors apicidin and n-butyrate suppress the proliferation of EoL-1 cells and induce differentiation into eosinophils by a decrease in the protein level of FIP1L1-PDGFRalpha without affecting the mRNA level for FIP1L1-PDGFRA. In this study, we analyzed the mechanism by which the protein level of FIP1L1-PDGFRalpha is decreased by apicidin and n-butyrate.

Methods: EoL-1 cells were incubated in the presence of the HDAC inhibitors apicidin, trichostatin A or n-butyrate. The protein levels of FIP1L1-PDGFRalpha and phosphorylated eIF-2alpha were determined by Western blotting. Actinomycin D and cycloheximide were used to block RNA synthesis and protein synthesis, respectively, in the chasing experiment of the amount of FIP1L1-PDGFRalpha protein.

Results: When apicidin- and n-butyrate-treated EoL-1 cells were incubated in the presence of actinomycin D, the decrease in the protein level of FIP1L1-PDGFRalpha was significantly enhanced when compared with controls. In contrast, the protein levels were not changed by cycloheximide among these groups. Apicidin and n-butyrate induced the continuous phosphorylation of eIF-2alpha for up to 8 days.

Conclusions: The decrease in the level of FIP1L1-PDGFRalpha protein by continuous inhibition of HDAC may be due to the decrease in the translation rate of FIP1L1-PDGFRA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Blotting, Western
  • Butyrates / pharmacology*
  • Cell Differentiation / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Enzyme Inhibitors / pharmacology*
  • Eosinophils / drug effects*
  • Eosinophils / metabolism
  • Eukaryotic Initiation Factor-2 / analysis
  • Eukaryotic Initiation Factor-2 / drug effects
  • Eukaryotic Initiation Factor-2 / metabolism*
  • Histone Deacetylase Inhibitors*
  • Histone Deacetylases / metabolism
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / metabolism
  • Oncogene Proteins, Fusion / analysis*
  • Oncogene Proteins, Fusion / drug effects
  • Oncogene Proteins, Fusion / metabolism
  • Peptides, Cyclic / pharmacology*
  • Receptor, Platelet-Derived Growth Factor alpha / analysis*
  • Receptor, Platelet-Derived Growth Factor alpha / drug effects
  • Receptor, Platelet-Derived Growth Factor alpha / metabolism
  • mRNA Cleavage and Polyadenylation Factors / analysis*
  • mRNA Cleavage and Polyadenylation Factors / drug effects
  • mRNA Cleavage and Polyadenylation Factors / metabolism

Substances

  • Butyrates
  • Enzyme Inhibitors
  • Eukaryotic Initiation Factor-2
  • Histone Deacetylase Inhibitors
  • Oncogene Proteins, Fusion
  • Peptides, Cyclic
  • apicidin
  • mRNA Cleavage and Polyadenylation Factors
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha
  • Histone Deacetylases